Cargando…

Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)

OBJECTIVES: The aim was to compare the impact of the first wave of the coronavirus disease 2019 (COVID-19) pandemic and lockdown measures on patients with rheumatic and musculoskeletal diseases (RMDs) in the UK and other European countries (OEC). METHODS: REUMAVID was an online cross-sectional surve...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephanie Rose, Garrido-Cumbrera, Marco, Navarro-Compán, Victoria, Correa-Fernández, José, Webb, Dale, Christen, Laura, Marzo-Ortega, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690324/
https://www.ncbi.nlm.nih.gov/pubmed/34988357
http://dx.doi.org/10.1093/rap/rkab098
_version_ 1784618631154368512
author Harrison, Stephanie Rose
Garrido-Cumbrera, Marco
Navarro-Compán, Victoria
Correa-Fernández, José
Webb, Dale
Christen, Laura
Marzo-Ortega, Helena
author_facet Harrison, Stephanie Rose
Garrido-Cumbrera, Marco
Navarro-Compán, Victoria
Correa-Fernández, José
Webb, Dale
Christen, Laura
Marzo-Ortega, Helena
author_sort Harrison, Stephanie Rose
collection PubMed
description OBJECTIVES: The aim was to compare the impact of the first wave of the coronavirus disease 2019 (COVID-19) pandemic and lockdown measures on patients with rheumatic and musculoskeletal diseases (RMDs) in the UK and other European countries (OEC). METHODS: REUMAVID was an online cross-sectional survey of seven European countries. The data collected included the following: demographics, lifestyle, employment, access to health-care services, disease-specific characteristics, the World Health Organization five well-being index (WHO-5), hospital anxiety and depression scale (HADS), visual analogue scale (VAS) disease activity, and the perceived acceptable symptom scale. RESULTS: One thousand eight hundred responses were received between April and July 2020 [UK, n = 558 (31.0%); OEC, n = 1242 (69.0%)]. UK patients were more likely to be older [mean (S.d.): UK 58.5 (13.4) years; OEC 50.0 (12.2) years], university educated [UK n = 302 (54.1%); OEC n = 572 (46.1%), quit smoking [UK n = 92 (59.4%); OEC n = 65 (16.2%)] and continue exercise [UK, n = 216 (49.2%); OEC, n = 228 (33.1%)], although, conversely, alcohol consumption increased [UK n = 99 (36.3%); OEC n = 98 (12.1%)]. UK patients felt informed about COVID-19 (UK 72.7%, OEC 57.4%) and kept their planned rheumatology [UK n = 87 (51.2%); OEC n = 213 (38.6%)] and/or general practice appointments [UK n = 87 (76.3%); OEC n = 310 (53.9%)]. Almost half the patients with RMDs reported a decline in health and well-being, although this was less common in UK patients [UK n = 214 (38.4%), OEC n = 618 (50.2%)], who reported better perceived acceptable symptom scale, VAS pain and HADS scores, but worse WHO-5 scores. CONCLUSIONS: UK RMD patients performed better in the physical and mental health domains tested, possibly owing to a less restrictive lockdown and better health-care access. These findings have implications for health-care services globally in planning patient care after the COVID-19 pandemic.
format Online
Article
Text
id pubmed-8690324
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86903242022-01-04 Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1) Harrison, Stephanie Rose Garrido-Cumbrera, Marco Navarro-Compán, Victoria Correa-Fernández, José Webb, Dale Christen, Laura Marzo-Ortega, Helena Rheumatol Adv Pract Original Article OBJECTIVES: The aim was to compare the impact of the first wave of the coronavirus disease 2019 (COVID-19) pandemic and lockdown measures on patients with rheumatic and musculoskeletal diseases (RMDs) in the UK and other European countries (OEC). METHODS: REUMAVID was an online cross-sectional survey of seven European countries. The data collected included the following: demographics, lifestyle, employment, access to health-care services, disease-specific characteristics, the World Health Organization five well-being index (WHO-5), hospital anxiety and depression scale (HADS), visual analogue scale (VAS) disease activity, and the perceived acceptable symptom scale. RESULTS: One thousand eight hundred responses were received between April and July 2020 [UK, n = 558 (31.0%); OEC, n = 1242 (69.0%)]. UK patients were more likely to be older [mean (S.d.): UK 58.5 (13.4) years; OEC 50.0 (12.2) years], university educated [UK n = 302 (54.1%); OEC n = 572 (46.1%), quit smoking [UK n = 92 (59.4%); OEC n = 65 (16.2%)] and continue exercise [UK, n = 216 (49.2%); OEC, n = 228 (33.1%)], although, conversely, alcohol consumption increased [UK n = 99 (36.3%); OEC n = 98 (12.1%)]. UK patients felt informed about COVID-19 (UK 72.7%, OEC 57.4%) and kept their planned rheumatology [UK n = 87 (51.2%); OEC n = 213 (38.6%)] and/or general practice appointments [UK n = 87 (76.3%); OEC n = 310 (53.9%)]. Almost half the patients with RMDs reported a decline in health and well-being, although this was less common in UK patients [UK n = 214 (38.4%), OEC n = 618 (50.2%)], who reported better perceived acceptable symptom scale, VAS pain and HADS scores, but worse WHO-5 scores. CONCLUSIONS: UK RMD patients performed better in the physical and mental health domains tested, possibly owing to a less restrictive lockdown and better health-care access. These findings have implications for health-care services globally in planning patient care after the COVID-19 pandemic. Oxford University Press 2021-12-04 /pmc/articles/PMC8690324/ /pubmed/34988357 http://dx.doi.org/10.1093/rap/rkab098 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Harrison, Stephanie Rose
Garrido-Cumbrera, Marco
Navarro-Compán, Victoria
Correa-Fernández, José
Webb, Dale
Christen, Laura
Marzo-Ortega, Helena
Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
title Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
title_full Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
title_fullStr Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
title_full_unstemmed Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
title_short Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1)
title_sort impact of covid-19 containment measures on patients with rheumatic and musculoskeletal disease in the uk and europe: the reumavid study (phase1)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690324/
https://www.ncbi.nlm.nih.gov/pubmed/34988357
http://dx.doi.org/10.1093/rap/rkab098
work_keys_str_mv AT harrisonstephanierose impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1
AT garridocumbreramarco impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1
AT navarrocompanvictoria impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1
AT correafernandezjose impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1
AT webbdale impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1
AT christenlaura impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1
AT marzoortegahelena impactofcovid19containmentmeasuresonpatientswithrheumaticandmusculoskeletaldiseaseintheukandeuropethereumavidstudyphase1